| dc.contributor.author | Onat, Altan | |
| dc.date.accessioned | 2021-03-05T09:08:51Z | |
| dc.date.available | 2021-03-05T09:08:51Z | |
| dc.date.issued | 2011 | |
| dc.identifier.citation | Onat A., "Metabolic syndrome: nature, therapeutic solutions and options", EXPERT OPINION ON PHARMACOTHERAPY, cilt.12, ss.1887-1900, 2011 | |
| dc.identifier.issn | 1465-6566 | |
| dc.identifier.other | av_9c7cb506-caf8-4f4a-a6d5-fbe0f047aec7 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/105154 | |
| dc.identifier.uri | https://doi.org/10.1517/14656566.2011.585462 | |
| dc.description.abstract | Introduction: Metabolic syndrome (MetS) defines the clustering in an individual of multiple metabolic abnormalities, based on central obesity and insulin resistance. In addition to its five components, prothrombotic and proinflammatory states are essential features. The significance of MetS lies in its close association with the risk of type 2 diabetes and cardiovascular disease (CVD). This field being an evolving one necessitated the current review. | |
| dc.language.iso | eng | |
| dc.subject | Eczacılık | |
| dc.subject | Temel Bilimler | |
| dc.subject | Temel Eczacılık Bilimleri | |
| dc.subject | Yaşam Bilimleri | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Yaşam Bilimleri (LIFE) | |
| dc.subject | Farmakoloji ve Toksikoloji | |
| dc.subject | FARMAKOLOJİ VE ECZACILIK | |
| dc.title | Metabolic syndrome: nature, therapeutic solutions and options | |
| dc.type | Makale | |
| dc.relation.journal | EXPERT OPINION ON PHARMACOTHERAPY | |
| dc.contributor.department | , , | |
| dc.identifier.volume | 12 | |
| dc.identifier.issue | 12 | |
| dc.identifier.startpage | 1887 | |
| dc.identifier.endpage | 1900 | |
| dc.contributor.firstauthorID | 201336 | |
